We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Talazoparib plus Enzalutamide Significantly Prolongs Survival in mCRPC: Final TALAPRO-2 Results Confirm Greatest Benefit in BRCA‑Altered Disease

MedXY Editorial Team•Nov 5, 2025•news
BRCA突变mCRPCmetastatic castration-resistant prostate cancerPARP Inhibitorprostate cancertalazoparib

Highlights

– TALAPRO-2 final analyses show a statistically significant overall survival (OS) benefit when talazoparib is added to enzalutamide in men with metastatic castration‑resistant prostate cancer (mCRPC), both in HRR‑deficient and unselected populations.

– The survival advantage is most pronounced in patients with BRCA1/2 alterations (HR ~0.50 in HRR‑deficient cohort; HR 0.55 in unselected HRR‑deficient subgroup), with a doubling of 4‑year OS in the BRCA subgroup.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Specialist Cardiovascular Referral Enhances Cholesterol Management in Prostate Cancer Patients: Insights from a Global Randomized TrialA randomized clinical trial demonstrates that routine cardiovascular specialist referral for prostate cancer patients improves cholesterol control but does not reduce major cardiovascular events over nearly 6 years.Sep 1, 2026Metabolic Dysfunction Following Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer: Clinical Implications and RisksThis study reveals a significant early onset of metabolic syndrome in men with prostate cancer treated with combined ADT and ARPI therapies, highlighting the necessity for multidisciplinary metabolic monitoring and interventions.Aug 15, 2026Systemic Therapy for Metastatic Castration-Resistant Prostate Cancer: Key Recommendations from the ASCO Living Guideline (Version 2026.1.4)A clear, practice-focused summary of the 2026 ASCO living guideline on systemic treatment of metastatic castration‑resistant prostate cancer, emphasizing biomarker-driven choices, sequencing, and new options such as 177Lu‑PSMA and PARP inhiAug 14, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Mathematical Biomarkers From First-Cycle PSA Dynamics May Predict Adaptive Therapy Outcomes in Prostate CancerA retrospective modeling study of 53 prostate cancer patients found that mechanism-based biomarkers derived from first-cycle PSA dynamics predicted time to progression and survival under adaptive therapy, outperforming standard PSA metrics. The approach could support personalized treatment scheduling.Aug 8, 2026
Predictive Mathematical Biomarkers Transform Personalized Adaptive Therapy in Prostate CancerMathematical biomarkers derived from initial PSA dynamics effectively predict adaptive therapy outcomes in prostate cancer, enabling personalized treatment strategies that outperform traditional PSA measures.Aug 8, 2026
Enhanced Detection of Clinically Significant Prostate Cancer: Insights from the Stockholm3-MRI Screening Study Two-Year Follow-upThe Stockholm3 test combined with MRI screening significantly improves detection of clinically significant prostate cancer compared to PSA alone, reducing missed cases and unnecessary biopsies in a population-based study with 2-year follow-Jun 25, 2026